Truist Securities Maintains Buy on Paycor HCM, Raises Price Target to $44

Truist Securities analyst Terry Tillman maintains Paycor HCM (NASDAQ:PYCR) with a Buy and raises the price target from $42 to $44.

byBenzinga Newsdesk

August 24, 2022

1 minute read

Truist Securities analyst Terry Tillman maintains Paycor HCM (NASDAQ:PYCR) with a Buy and raises the price target from $42 to $44.

Analyst Ratings

Expert Ratings For Arcturus Therapeutics

By Benzinga Insights

Today, 10:57 PM

Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:

ARCT

Northwest Natural Holding Q2 EPS $(0.02) Beats $(0.13) Estimate, Sales $148.92M Beat $142.63M Estimate

By Benzinga Newsdesk

Today, 10:57 PM

Northwest Natural Holding (NYSE:NWN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.13) by 84.62 percent. This is a 88.24 percent increase over losses of $(0.17) per share

NWN

Here’s Why Morgan Stanley Sees Sharp Upside In This IT Company

By Anusuya Lahiri

Today, 10:57 PM

Morgan Stanley analyst James Faucette reiterated his Overweight rating and $140 price target on Affirm Holdings Inc (NASDAQ:AFRM). The price target implies an…

AFRM

Hollister Biosciences Stock Down Slightly On $17.6M Q2 2021 Revenue Report, $3.2M Of Adjusted EBITDA

By Jelena Martinovic

Today, 10:57 PM

Cannabis branding company Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) reported its financial and operating results on Thursday for the second quarter of 2021, touting a significant growth in revenue which amounted to $17.6 million.

CSE:HOLL

Truist Securities Maintains Buy on Paycor HCM, Raises Price Target to $44

Related Posts

Expert Ratings For Arcturus Therapeutics

Northwest Natural Holding Q2 EPS $(0.02) Beats $(0.13) Estimate, Sales $148.92M Beat $142.63M Estimate

Here’s Why Morgan Stanley Sees Sharp Upside In This IT Company

Hollister Biosciences Stock Down Slightly On $17.6M Q2 2021 Revenue Report, $3.2M Of Adjusted EBITDA